SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy
Journal of Nuclear Medicine · 2023-09 · 64 (9) · 1417-1423
DOI: 10.2967/jnumed.123.265952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.06.2023. Verfasst von Thomas A Hope und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA) is a transmembrane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
- University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota.
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
- Department of Radiology, University of Washington, Seattle, Washington.
- Department of Radiology, Brigham and Women's Hospital, and Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts.
Zitieren
APA
Hope, T. A., Antonarakis, E. S., Bodei, L., Calais, J., Iravani, A., Jacene, H., Koo, P. J., Morgans, A. K., Osborne, J. R., Tagawa, S. T., Taplin, M. E., Sartor, O., & Morris, M. J. (2023). SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy. Journal of Nuclear Medicine, 64(9), 1417-1423. https://doi.org/10.2967/jnumed.123.265952
Vancouver
Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, et al. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy. Journal of Nuclear Medicine. 2023;64(9):1417-1423. doi:10.2967/jnumed.123.265952
BibTeX
@article{Hope2023,
author = {Hope, Thomas A and Antonarakis, Emmanuel S and Bodei, Lisa and Calais, Jeremie and Iravani, Amir and Jacene, Heather and Koo, Phillip J and Morgans, Alicia K and Osborne, Joseph R and Tagawa, Scott T and Taplin, Mary-Ellen and Sartor, Oliver and Morris, Michael J},
title = {SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177 Lu-PSMA-617 Radionuclide Therapy},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {9},
pages = {1417--1423},
doi = {10.2967/jnumed.123.265952}
}
EUVIMED